Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Chugai Pharmaceutical to Introduce iPad2 to All MRs and MAs from Mid-January
November 29, 2011
- Mitsubishi Tanabe, Alfresa Obtain Approval for Additional Indication for Sleep Disorder Treatment Modiodal
November 29, 2011
- Pfizer Japan Launches 20 Generics with 10 APIs
November 29, 2011
- Kyowa Pharmaceutical Industry to Launch 2 Generic Drugs Made in India in 2012
November 28, 2011
- Nexium Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
November 28, 2011
- Novartis Files NDA for NVA237 for COPD in Japan
November 28, 2011
- M3 Survey Shows Doctors Want KOL Who Are “Easy to Understand” and Have “Extensive Experience”
November 28, 2011
- Iressa Approved for EGFR Mutation-Positive NSCLC: AZ
November 28, 2011
- Yakult Receives Approval for Changes to Dosage, Administration for Elplat as Post-Operative Therapy for Colorectal Cancer
November 28, 2011
- Chugai Pharmaceutical Obtains Approval for Additional Indication for Anticancer Agent Herceptin
November 28, 2011
- Additional Indication of Solar Keratosis Approved for Mochida Pharmaceutical's Beselna Cream
November 28, 2011
- 26 Major JPMA Member Companies Report Declines in Sales, Profits, with 8.8% Drop in Overseas Sales
November 25, 2011
- Takeda Files NDA for Fixed-Dose Combination of DPP-4 Alogliptin, Metformin with US FDA
November 25, 2011
- MTPC, Novartis Pharma: Imusera 0.5 mg/Gilenya 0.5 mg for Treatment of MS
November 25, 2011
- Asahi Kasei: Teribone SC Injection 56.5 µg for Treatment of Osteoporosis
November 25, 2011
- MTPC: Telavic Tablets 250 mg to Treat Chronic Hepatitis C
November 25, 2011
- 25 Leading Drug Makers Report Overall Decline in Sales, Profits in 1st Half
November 24, 2011
- Astellas President Hatanaka Highly Expects “Bio-Lead Project
November 22, 2011
- Sakai Chemical to Make Kaigen Wholly Owned Subsidiary
November 22, 2011
- ASKA Aims at ¥20 Billion Sales in Generics Business: President Yamaguchi
November 22, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…